Foghorn Therapeutics furnishes September 2023 corporate presentation

Foghorn Therapeutics Inc.

Presentation highlights chromatin regulatory platform for precision oncology therapies.
No financial results, clinical data, or guidance changes disclosed in the exhibit.
Materials intended for investor meetings; no material new operational update provided.

item 7.01 item 9.01

Foghorn Therapeutics Inc. filing history →

Source: SEC EDGAR

accession 0001628280-23-031771

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.